Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629002 | 1.00 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2450264 | 0.88 | CHRM2 (0.37) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15776484 | 0.86 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15776483 | 0.86 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13541170 | 0.82 | HSD17B10 (0.35) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13541087 | 0.82 | HSD17B10 (0.35) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14578712 | 0.81 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14612197 | 0.81 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL19075563 | 0.79 | RIPK1 (0.35) | HSD17B10 | |
| SCHEMBL5371270 | 0.77 | KMT2A (0.40) | SMN1; SMN2ATMHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215870-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2928868-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017060914-A2 | PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH | Krisani Biosciences (P) Ltd. (IN) | 2017-04-13 | — | — | WO | disclosed |
| US-9303012-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-0932606-A1 | INHIBITORS OF PRENYL TRANSFERASES | Biomeasure Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5773455-A | Inhibitors of prenyl transferases | BIOMEASURE, INCORPORATED (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998000409-A1 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INCORPORATED (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| CN-1114961-A | Peptide inhibitors of cell adhesion | TANABE SEIYAKU CO (JP) | 1996-01-17 | — | — | CN | disclosed |
| EP-0677060-A1 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015958-A2 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1994-07-21 | — | — | WO | disclosed |
| EP-0538399-A4 | — | — | 1994-05-04 | — | — | EP | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | CNR2, CNR1, GPR52 | HSD17B10 3567/4885CHRM2 62/4885CHRM1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.